Data gathered: July 9
AI Stock Analysis - Arcutis Biotherapeutics (ARQT)
Analysis generated December 16, 2024. Powered by Chat GPT.
Arcutis Biotherapeutics is a leading biopharmaceutical company dedicated to developing novel treatments for dermatological conditions. With a strong focus on innovation and patient-centric care, the company aims to address unmet clinical needs in dermatology through its robust pipeline of drug candidates. Founded on scientific rigor and clinical expertise, Arcutis Biotherapeutics has been making strides in the therapeutic landscape, particularly in conditions like psoriasis and atopic dermatitis.
Stock Alerts - Arcutis Biotherapeutics (ARQT)
 |
Arcutis Biotherapeutics | July 3 Insider Alert: Welgus Howard G. is continuing selling shares |
|
Arcutis Biotherapeutics | June 24 AI Score is up by 23.4% in the last couple of days. |
|
Arcutis Biotherapeutics | June 21 Insider Alert: Welgus Howard G. is selling shares |
|
Arcutis Biotherapeutics | June 18 Insider Alert: Heron Patrick J is continuing buying shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Arcutis Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 19,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | 17 | Sign up | Sign up | Sign up |
| Patents | 36 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 7 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,445 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 19 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,424 | Sign up | Sign up | Sign up |
| Twitter Followers | 594 | Sign up | Sign up | Sign up |
| Twitter Mentions | 13 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 378 | Sign up | Sign up | Sign up |
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
| Price | $13.76 |
| Target Price | Sign up |
| Volume | 1,450,000 |
| Market Cap | $1.65B |
| Year Range | $8.31 - $17.29 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3 - Yahoo |
 |
Arcutis Biotherapeutics assumed with an Overweight at Morgan StanleyJuly 3 - Thefly.com |
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis DirectionJune 27 - SeekingAlpha |
|
Arcutis Biotherapeutics, Inc. Announces ZORYVE®? (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic DermatitisJune 25 - Finnhub |
|
Arcutis Biotherapeutics: Another Approval Under Their BeltJune 24 - SeekingAlpha |
|
 |
SG Americas Securities LLC Has $509,000 Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)June 23 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 66M | 8.8M | 57M | -25M | 0 | -0.200 |
| Q4 '24 | 71M | 6.9M | 64M | -11M | -4.5M | -0.090 |
| Q3 '24 | 45M | 5.5M | 39M | -42M | -33M | -0.330 |
| Q2 '24 | 31M | 3.5M | 27M | -52M | -44M | -0.420 |
| Q1 '24 | 50M | 3.3M | 46M | -35M | -31M | -0.320 |
Insider Transactions View All
| Welgus Howard G. filed to sell 100,206 shares at $13.8. July 2 '25 |
| Welgus Howard G. filed to sell 109,414 shares at $13.4. June 20 '25 |
| Heron Patrick J filed to buy 27,448 shares at $13.1. June 17 '25 |
| Heron Patrick J filed to buy 24,802 shares at $13.4. June 6 '25 |
| Heron Patrick J filed to buy 24,424 shares at $13.3. June 6 '25 |
Similar companies
Read more about Arcutis Biotherapeutics (ARQT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arcutis Biotherapeutics?
The Market Cap of Arcutis Biotherapeutics is $1.65B.
What is the current stock price of Arcutis Biotherapeutics?
Currently, the price of one share of Arcutis Biotherapeutics stock is $13.76.
How can I analyze the ARQT stock price chart for investment decisions?
The ARQT stock price chart above provides a comprehensive visual representation of Arcutis Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcutis Biotherapeutics shares. Our platform offers an up-to-date ARQT stock price chart, along with technical data analysis and alternative data insights.
Does ARQT offer dividends to its shareholders?
As of our latest update, Arcutis Biotherapeutics (ARQT) does not offer dividends to its shareholders. Investors interested in Arcutis Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arcutis Biotherapeutics?
Some of the similar stocks of Arcutis Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.